These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 15019761)

  • 1. A new and more robust test of QALYs.
    Doctor JN; Bleichrodt H; Miyamoto J; Temkin NR; Dikmen S
    J Health Econ; 2004 Mar; 23(2):353-67. PubMed ID: 15019761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New tests of QALYs when health varies over time.
    Bleichrodt H; Filko M
    J Health Econ; 2008 Sep; 27(5):1237-49. PubMed ID: 18644640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [QALYS or not QALYS: that is the question?].
    Moatti JP; Auquier P; Le Coroller AG; Macquart-Moulin G
    Rev Epidemiol Sante Publique; 1995 Dec; 43(6):573-83. PubMed ID: 8552855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Community or patient preferences for cost-effectiveness of cardiac rehabilitation: does it matter?
    Oldridge N; Furlong W; Perkins A; Feeny D; Torrance GW
    Eur J Cardiovasc Prev Rehabil; 2008 Oct; 15(5):608-15. PubMed ID: 18800005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjusting to changes in health: implications for cost-effectiveness analysis.
    Sharma R; Stano M; Haas M
    J Health Econ; 2004 Mar; 23(2):335-51. PubMed ID: 15019760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testing rank-dependent utility theory for health outcomes.
    Oliver A
    Health Econ; 2003 Oct; 12(10):863-71. PubMed ID: 14508870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A utility-theoretic model for QALYs and willingness to pay.
    Klose T
    Health Econ; 2003 Jan; 12(1):17-31. PubMed ID: 12483758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P; De Groote K; Annemans L
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Not all "quality-adjusted life years" are equal.
    Marra CA; Marion SA; Guh DP; Najafzadeh M; Wolfe F; Esdaile JM; Clarke AE; Gignac MA; Anis AH
    J Clin Epidemiol; 2007 Jun; 60(6):616-24. PubMed ID: 17493521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporating feelings related to the uncertainty about future health in utility measurement.
    Gandjour A
    Health Econ; 2008 Oct; 17(10):1207-13. PubMed ID: 18074407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient preferences and cost-utility analysis.
    Elnitsky CA; Stone P
    Appl Nurs Res; 2005 May; 18(2):74-6. PubMed ID: 15991103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A value-based medicine cost-utility analysis of idiopathic epiretinal membrane surgery.
    Gupta OP; Brown GC; Brown MM
    Am J Ophthalmol; 2008 May; 145(5):923-8. PubMed ID: 18329000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On future non-medical costs in economic evaluations.
    Liljas B; Karlsson GS; Stålhammar NO
    Health Econ; 2008 May; 17(5):579-91. PubMed ID: 17787027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are decisions using cost-utility analyses robust to choice of SF-36/SF-12 preference-based algorithm?
    Pickard AS; Wang Z; Walton SM; Lee TA
    Health Qual Life Outcomes; 2005 Mar; 3():11. PubMed ID: 15748287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A note on the nature of utility in time and health and implications for cost utility analysis.
    Buckingham KJ; Devlin NJ
    Soc Sci Med; 2009 Jan; 68(2):362-7. PubMed ID: 19019518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The predictive validity of prospect theory versus expected utility in health utility measurement.
    Abellan-Perpiñan JM; Bleichrodt H; Pinto-Prades JL
    J Health Econ; 2009 Dec; 28(6):1039-47. PubMed ID: 19833400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The construction of standard gamble utilities.
    van Osch SM; Stiggelbout AM
    Health Econ; 2008 Jan; 17(1):31-40. PubMed ID: 17410521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value-based medicine comparative effectiveness and cost-effectiveness of penetrating keratoplasty for keratoconus.
    Roe RH; Lass JH; Brown GC; Brown MM
    Cornea; 2008 Oct; 27(9):1001-7. PubMed ID: 18812762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in Canadian adults with chronic immune thrombocytopenic purpura.
    Xie F; Blackhouse G; Assasi N; Campbell K; Levin M; Bowen J; Tarride JE; Pi D; Goeree R
    Clin Ther; 2009 May; 31(5):1082-91; discussion 1066-8. PubMed ID: 19539109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.